Merck Partners With Dutch University On Quest For Bovine Mastitis Vaccine



Published:

Dutch company Merck Animal Health embarked on the development of new vaccination strategies to protect against bovine mastitis by signing an agreement with the Department of Medical Microbiology of the University Medical Center Utrecht and the Faculty of Veterinary Medicine of Utrecht University in the Netherlands, Merck reported today.

The project, titled “Evasion Molecules in Bovine Mastitis Vaccines” (EVAC), aims to develop a series of vaccines against difficult-to-treat infections with certain bacteria known to cause bovine mastitis, such as Staphylococcus aureu, Streptococcus uberis and Escheria coli. Development of vaccines against bovine mastitis have been hampered due to the relevant pathogens’ creation of “immune evasion molecules” that block or interfere with important processes in the immune system of the cow, Merck said. Evasion molecules also appear to interfere with the immune response that is provoked against vaccines. Therefore, despite the induction of high antibody levels, the clinical efficacy of most mastitis vaccines developed so far have been poor, Merck said.

Through the EVAC project, 25 of the 50 evasion molecules have been identified and characterized, and recombinant versions of the proteins have been produced. Combinations of such evasion molecules will be added to traditional antigens in candidate vaccines. Merck expects these vaccines to raise the neutralizing antibodies against immune evasion molecules in the animal, leading the evasion system of the bacteria to become impaired and allowing the antibodies to neutralize the mastitis-causing pathogens.

The EVAC project is part of the Alternatives for Antibiotics (ALTANT) program, coordinated by public-private research consortium Immuno Valley. The technologies developed within the ALTANT program may result in an efficacious vaccine against bovine mastitis and, in combination with current therapeutic tools, can result in unprecedented possibilities to control the disease, according to Rene Aerts, Ph.D., vice president of global biological research and development at Merck Animal Health.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Study May Lead to Early Diagnosis of Feline Kidney Disease

The biomarker SDMA identified the onset of kidney disease an average of 17 months earlier in cats and in one case four years earlier.

Merck Launches Overseas Veterinarian Exchange

The Nobivac Global Vet Exchange Program allows practitioners to observe how veterinary medicine is performed in other countries.

Petco Buying Drs. Foster and Smith

Co-founders Race Foster and Marty Smith will stay with Drs. Foster and Smith when Petco takes ownership and branches into drug sales in early 2015.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module